Botulinum Toxins, Type A
14
3
3
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
36%
5 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (14)
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)
The Effects of Preoperative Botulinum Toxin A Injection on Respiratory System Function
Effect of Blood Flow by Botulinum Toxin Injection for Severe Peripheral Artery Occlusive Disease
Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache
Muscle Weakness Duration After Single Botulinum Toxin Injection in Masseter
Higher Doses of Botulinum Toxin in the Treatment of Gummy Smile
Application of Botulinum Toxin at the Yonsei Point for the Treatment of Gummy Smile
Effects of Dose and Injection Site for Gummy Smile Treatment With Botulinum Type A
Therapeutic Effect of Botulinum Toxin A for the Treatment of Plantar Fasciitis.
Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm
Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies
Intraprostatic Injection of Botulinum Toxin A Versus Ethanol for Treatment of Patients With Benign Prostatic Hyperplasia
Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility